Safety and Efficacy of SPARC1203 in Allergic Rhinitis

Summary

This study will assess safety and efficacy of SPARC1203 delivered via nasal spray in patients with allergic rhinitis

Timeline

Start

2012-06

Primary completion

2012-11

Completion

2013-03

Outcome

Met primary endpoint

paper Statistically significant improvements in TNSS from baseline to days 15 and 16 were observed with all S0597 doses vs placebo (P = .0005 overall) PMID 26272281 ↗

Publications

• Badorrek P, Hohlfeld JM, Krug N, Joshi A, Raut A. Efficacy and safety of a novel nasal steroid, S0597, in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2015 Oct;115(4):325-329.e1. doi: 10.1016/j.anai.2015.07.016. Epub 2015 Aug 11.

Drugs

Indications